Translating molecular advances in fragile x syndrome into therapy

A review

Randi J Hagerman, Vincent Des-Portes, Fabrizio Gasparini, Sébastien Jacquemont, Baltazar Gomez-Mancilla

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utili7ed with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.

Original languageEnglish (US)
JournalJournal of Clinical Psychiatry
Volume75
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Fragile X Syndrome
Neurobehavioral Manifestations
Therapeutics
Neurologic Manifestations
Research
Animal Models
Mutation
Translating
Syndrome
Therapy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Translating molecular advances in fragile x syndrome into therapy : A review. / Hagerman, Randi J; Des-Portes, Vincent; Gasparini, Fabrizio; Jacquemont, Sébastien; Gomez-Mancilla, Baltazar.

In: Journal of Clinical Psychiatry, Vol. 75, No. 4, 2014.

Research output: Contribution to journalArticle

Hagerman, Randi J ; Des-Portes, Vincent ; Gasparini, Fabrizio ; Jacquemont, Sébastien ; Gomez-Mancilla, Baltazar. / Translating molecular advances in fragile x syndrome into therapy : A review. In: Journal of Clinical Psychiatry. 2014 ; Vol. 75, No. 4.
@article{ea6bbcea24b64823aa97d26122d75b45,
title = "Translating molecular advances in fragile x syndrome into therapy: A review",
abstract = "Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utili7ed with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.",
author = "Hagerman, {Randi J} and Vincent Des-Portes and Fabrizio Gasparini and S{\'e}bastien Jacquemont and Baltazar Gomez-Mancilla",
year = "2014",
doi = "10.4088/JCP.73r08774",
language = "English (US)",
volume = "75",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Translating molecular advances in fragile x syndrome into therapy

T2 - A review

AU - Hagerman, Randi J

AU - Des-Portes, Vincent

AU - Gasparini, Fabrizio

AU - Jacquemont, Sébastien

AU - Gomez-Mancilla, Baltazar

PY - 2014

Y1 - 2014

N2 - Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utili7ed with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.

AB - Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utili7ed with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.

UR - http://www.scopus.com/inward/record.url?scp=84899730390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899730390&partnerID=8YFLogxK

U2 - 10.4088/JCP.73r08774

DO - 10.4088/JCP.73r08774

M3 - Article

VL - 75

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -